Myriad Genetics to Present Five Studies at the Seventh International Symposium on Hereditary Breast and Ovarian Cancer

On May 4, 2018 Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, reported that it will present results from five studies at the Seventh International Symposium on Hereditary Breast and Ovarian Cancer annual meeting to be held May 8 to 11, 2018 in Montréal, Canada (Press release, Myriad Genetics, MAY 4, 2018, View Source [SID1234526136]). More information about the symposium can be found here: View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to presenting important new research on risk associated with breast and ovarian cancer gene mutations," said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetics. "Our presentations will highlight Myriad’s ongoing commitment to research, advances to state-of-the-art hereditary cancer risk assessment and the highest quality of clinical testing."

About Myriad myRisk Hereditary Cancer

The Myriad myRisk Hereditary Cancer test uses an extensive number of sophisticated technologies and proprietary algorithms in an 850 step laboratory process to evaluate 28 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma. For more information visit: View Source

About riskScore

riskScore is a clinically validated personalized medicine tool that enhances Myriad’s myRisk Hereditary Cancer test. riskScore helps to further predict a women’s lifetime risk of developing breast cancer using clinical risk factors and genetic-markers throughout the genome. The test incorporates data from greater than 80 single nucleotide polymorphisms identified through 20 years of genome wide association studies in breast cancer and was validated in our laboratory to predict breast cancer risk in women of European descent. This data is then combined with a best-in-class family and personal history algorithm, the Tyrer-Cuzick model, to provide more patients with individualized breast cancer risk.